Financial Contrast: vTv Therapeutics (NASDAQ:VTVT) and 89bio (NASDAQ:ETNB)

89bio (NASDAQ:ETNBGet Rating) and vTv Therapeutics (NASDAQ:VTVTGet Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Profitability

This table compares 89bio and vTv Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
89bio N/A -73.63% -62.29%
vTv Therapeutics -313.93% N/A -55.69%

Earnings & Valuation

This table compares 89bio and vTv Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
89bio N/A N/A -$90.12 million ($5.00) -0.61
vTv Therapeutics $4.01 million 9.24 -$12.99 million ($0.24) -1.72

vTv Therapeutics has higher revenue and earnings than 89bio. vTv Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

91.1% of 89bio shares are held by institutional investors. Comparatively, 7.4% of vTv Therapeutics shares are held by institutional investors. 11.8% of 89bio shares are held by company insiders. Comparatively, 1.4% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

89bio has a beta of 2.82, meaning that its stock price is 182% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of -1.43, meaning that its stock price is 243% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for 89bio and vTv Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
89bio 0 0 5 1 3.17
vTv Therapeutics 0 0 2 0 3.00

89bio presently has a consensus price target of $41.43, suggesting a potential upside of 1,249.46%. vTv Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 1,235.92%. Given 89bio’s stronger consensus rating and higher possible upside, research analysts clearly believe 89bio is more favorable than vTv Therapeutics.

Summary

89bio beats vTv Therapeutics on 8 of the 13 factors compared between the two stocks.

About 89bio (Get Rating)

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

About vTv Therapeutics (Get Rating)

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.